Tags

Type your tag names separated by a space and hit enter

[Statins diabetogenicity: are all the same? state of art].
Clin Investig Arterioscler 2015 May-Jun; 27(3):148-58CI

Abstract

Statins are the cornerstone of cardiovascular prevention for general population, and in patients with type 2 diabetes mellitus (T2DM). However, statin therapy predisposes to type 2 diabetes, particularly in patients with predisposition to this condition. Some statins have been associated with increases in blood glucose in patients with or without DM2, and others have shown to have neutral effects, varying from one another their glucose or diabetogenic capacity. In many statin trials the incidence of DM2 has not been systematically evaluated and others the power to detect differences between statins is lacking. Evidence highest quality available comes from the meta-analysis of controlled clinical trials. The only controlled clinical trial to evaluate the incidence of new-onset T2DM is the J-PREDICT conducted with pitavastatin in patients with abnormal glucose tolerance. Preliminary results of this study show that pitavastatin is associated with a significant decrease in the incidence of de novo T2DM compared to only modification lifestyle. Therefore, pitavastatin may be an appropriate therapeutic alternative of choice to reduce vascular risk in patients with T2DM or at risk of presenting it.

Authors+Show Affiliations

Medical Affairs Cardiovascular Area, ESTEVE, Barcelona, España. Electronic address: 29815jrt@gmail.com.Unidad de Riesgo Cardiovascular y Lípidos, Servicio de Medicina Interna, Hospital General Universitario Gregorio Marañón, Madrid, España.Unidad de Riesgo Cardiovascular y Lípidos, Servicio de Endocrinología y Nutrición, Hospital del Mar, Barcelona, España.Unidad de Riesgo Cardiovascular y Lípidos, Servicio de Medicina Interna, Hospital Universitario de Bellvitge, Barcelona, España.

Pub Type(s)

Journal Article
Review

Language

spa

PubMed ID

25835612

Citation

Rius Tarruella, Joan, et al. "[Statins Diabetogenicity: Are All the Same? State of Art]." Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis, vol. 27, no. 3, 2015, pp. 148-58.
Rius Tarruella J, Millán Núñez-Cortés J, Pedro-Botet J, et al. [Statins diabetogenicity: are all the same? state of art]. Clin Investig Arterioscler. 2015;27(3):148-58.
Rius Tarruella, J., Millán Núñez-Cortés, J., Pedro-Botet, J., & Pintó Sala, X. (2015). [Statins diabetogenicity: are all the same? state of art]. Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis, 27(3), pp. 148-58. doi:10.1016/j.arteri.2015.02.001.
Rius Tarruella J, et al. [Statins Diabetogenicity: Are All the Same? State of Art]. Clin Investig Arterioscler. 2015;27(3):148-58. PubMed PMID: 25835612.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Statins diabetogenicity: are all the same? state of art]. AU - Rius Tarruella,Joan, AU - Millán Núñez-Cortés,Jesús, AU - Pedro-Botet,Juan, AU - Pintó Sala,Xavier, Y1 - 2015/03/31/ PY - 2015/02/02/received PY - 2015/02/03/accepted PY - 2015/4/4/entrez PY - 2015/4/4/pubmed PY - 2016/12/15/medline KW - Cardiovascular disease KW - Diabetes mellitus tipo 2 KW - Disglicemia KW - Dysglycemia KW - Enfermedad cardiovascular KW - Estatinas KW - HbA1c KW - Prevención KW - Prevention KW - Statins KW - Type 2 diabetes mellitus SP - 148 EP - 58 JF - Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis JO - Clin Investig Arterioscler VL - 27 IS - 3 N2 - Statins are the cornerstone of cardiovascular prevention for general population, and in patients with type 2 diabetes mellitus (T2DM). However, statin therapy predisposes to type 2 diabetes, particularly in patients with predisposition to this condition. Some statins have been associated with increases in blood glucose in patients with or without DM2, and others have shown to have neutral effects, varying from one another their glucose or diabetogenic capacity. In many statin trials the incidence of DM2 has not been systematically evaluated and others the power to detect differences between statins is lacking. Evidence highest quality available comes from the meta-analysis of controlled clinical trials. The only controlled clinical trial to evaluate the incidence of new-onset T2DM is the J-PREDICT conducted with pitavastatin in patients with abnormal glucose tolerance. Preliminary results of this study show that pitavastatin is associated with a significant decrease in the incidence of de novo T2DM compared to only modification lifestyle. Therefore, pitavastatin may be an appropriate therapeutic alternative of choice to reduce vascular risk in patients with T2DM or at risk of presenting it. SN - 1578-1879 UR - https://www.unboundmedicine.com/medline/citation/25835612/[Statins_diabetogenicity:_are_all_the_same_state_of_art]_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0214-9168(15)00007-8 DB - PRIME DP - Unbound Medicine ER -